Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP)

BACKGROUND: The BCR-ABL tyrosine kinase is a well validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (IM), a tyrosine kinase inhibitor is highly effective in the treatment of chronic phase CML. BCR – ABL transcripts have been well established as a molecular marker to d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Med J Armed Forces India
Autors principals: Nair, Velu, Sharma, Ajay, Kotwal, Jyoti, Bhikshapathy, M., Mishra, D.K., Das, Satyaranjan, Sharma, Sanjeevan, Kapoor, Rajan, Singh, Jasjit, Nair, Vivek, Uday, Y., Kotwal, Atul
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2014
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223192/
https://ncbi.nlm.nih.gov/pubmed/25382903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mjafi.2014.07.005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars